Clinical Outcomes of a Hybrid Model Approach to Applied Behavioral Analysis Treatment.

applied behavior analysis autism hybrid model aba patient outcomes treatment

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Mar 2023
Historique:
accepted: 24 03 2023
medline: 1 4 2023
entrez: 31 3 2023
pubmed: 1 4 2023
Statut: epublish

Résumé

Objective This study examines the implementation of a hybrid applied behavioral analysis (ABA) treatment model to determine its impact on autism spectrum disorder (ASD) patient outcomes.  Methods Retrospective data were collected for 25 pediatric patients to measure progress before and after the implementation of a hybrid ABA treatment model under which therapists consistently captured session notes electronically regarding goals and patient progress. ABA treatment was streamlined for consistent delivery, with improved software utilization for tracking scheduling and progress. Eleven goals within three domains (behavioral, social, and communication) were examined.  Results After the implementation of the hybrid model, the goal success rate improved by 9.7% compared to the baseline; 41.8% of goals showed improvement, 38.4% showed a flat trend, and 19.8% showed deterioration. Multiple goals trended upwards in 76% of the patients.  Conclusion This pilot study demonstrated that enhancing the consistency with which ABA treatment is monitored/delivered can improve patient outcomes as seen through improved attainment of goals.

Identifiants

pubmed: 36998917
doi: 10.7759/cureus.36727
pmc: PMC10047423
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e36727

Informations de copyright

Copyright © 2023, Garikipati et al.

Déclaration de conflit d'intérêts

The authors have declared financial relationships, which are detailed in the next section.

Références

Psychiatry Investig. 2020 May;17(5):432-443
pubmed: 32375461
J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):237-57
pubmed: 24472258
Brain Inform. 2023 Mar 2;10(1):7
pubmed: 36862316
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD003681
pubmed: 22161380
Behav Anal. 2005;28(2):99-131
pubmed: 22478444
Brain Inform. 2022 Jul 25;9(1):16
pubmed: 35879626
Neurosci Bull. 2017 Apr;33(2):183-193
pubmed: 28213805
AMIA Jt Summits Transl Sci Proc. 2019 May 06;2019:722-731
pubmed: 31259029
Psychol Bull. 2020 Jan;146(1):1-29
pubmed: 31763860
Sci Rep. 2020 Mar 19;10(1):5014
pubmed: 32193406
J Dev Behav Pediatr. 2014 May;35(4):247-56
pubmed: 24799263
Res Dev Disabil. 2014 Dec;35(12):3632-44
pubmed: 25241118
BMC Pediatr. 2022 May 27;22(1):314
pubmed: 35624439
Ann Clin Psychiatry. 2009 Jul-Sep;21(3):162-73
pubmed: 19758537
Behav Ther. 2015 Jan;46(1):7-19
pubmed: 25526831
Res Dev Disabil. 2005 Jul-Aug;26(4):359-83
pubmed: 15766629
Health Serv Insights. 2020 Jan 27;13:1178632920902141
pubmed: 32063709
Behav Anal Pract. 2022 Jul 7;:1-9
pubmed: 35822165
Pediatr Res. 2022 Apr;91(5):1028-1035
pubmed: 33767375
Transl Psychiatry. 2017 Sep 19;7(9):e1234
pubmed: 28925999
Res Dev Disabil. 2017 Nov;70:185-197
pubmed: 28963874
Pediatrics. 2007 Nov;120(5):1162-82
pubmed: 17967921
J Autism Dev Disord. 2011 Oct;41(10):1303-20
pubmed: 21161577

Auteurs

Anurag Garikipati (A)

Research and Development, Montera, Inc. DBA Forta, San Francisco, USA.

Madalina Ciobanu (M)

Research and Development, Montera, Inc. DBA Forta, San Francisco, USA.

Navan Preet Singh (NP)

Engineering, Montera, Inc. DBA Forta, San Francisco, USA.

Gina Barnes (G)

Research and Development, Montera, Inc. DBA Forta, San Francisco, USA.

Jenna Decurzio (J)

Research and Development, Montera, Inc. DBA Forta, San Francisco, USA.

Qingqing Mao (Q)

Research and Development, Montera, Inc. DBA Forta, San Francisco, USA.

Ritankar Das (R)

Executive Leadership, Montera, Inc. DBA Forta, San Francisco, USA.

Classifications MeSH